English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, January 19, 2018
エーザイ、抗がん剤E7046(プロスタグランジンE2受容体タイプ4拮抗剤)についてAdlai Nortye社とライセンス契約を締結
エーザイ・EAファーマ・持田製薬、「グーフィス錠 5mg」の日本においての慢性便秘症に係る製造販売承認を取得
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046
Thursday, January 18, 2018
Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the United States
エーザイ、制吐剤「ALOXI(R)」に関する米国の特許侵害訴訟について
Thursday, January 11, 2018
エーザイ、中国の新蘇州工場において固体剤生産棟が竣工
Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China
Tuesday, January 9, 2018
Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan
Eisai and Merck & Co. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA and KEYTRUDA

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575